PFIZER INC. for PFIZER INC.
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report (this page) | Jul 21, 2025 | $3,490,000 | Replaced |
| 2nd Quarter - Amendment | Aug 18, 2025 | $3,710,000 | Replaced |
| 2nd Quarter - Amendment | Oct 20, 2025 | $3,730,000 | Yes |
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development
| Lobbyist | Covered position, as disclosed |
|---|---|
| MATTHEW STROIA | — |
| JENNIFER SWENSON WALTON | — |
| ANGELA BOOTHE WILES | — |
Health Issues HCR
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 1 - One Big Beautiful Bill Act CDC Reform Vaccine Policy Reconciliation Research & Development HR 946 - ORPHAN Cures Act HR 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program HR 2214 - DRUG Act HR 2450 - Prescription Drug Transparency and Affordability Act PL 117-328 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Biosimilars Access, Reimbursement and Reform 340B Reform Prescription Drug User Fee Act (PDUFA) Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage and Access Intellectual Property Protections PBM Reform Cancer Policies Drug Pricing
| Lobbyist | Covered position, as disclosed |
|---|---|
| PAULA BURG | — |
| FRANCISCO CARRILLO | — |
| EMILY MUELLER | — |
| CATHERINE ROBINSON | — |
| MATTHEW STROIA | — |
| JENNIFER SWENSON WALTON | — |
| ANGELA BOOTHE WILES | — |
Medicare/Medicaid MMM
S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 832 - EPIC Act of 2025 HR 946 - ORPHAN Cures Act HR 2450 - Prescription Drug Transparency and Affordability Act Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients PBM Reform Medicaid Prescription Drug Access Digital Therapeutics
| Lobbyist | Covered position, as disclosed |
|---|---|
| PAULA BURG | — |
| FRANCISCO CARRILLO | — |
| EMILY MUELLER | — |
| MATTHEW STROIA | — |
| ANGELA BOOTHE WILES | — |
Taxation/Internal Revenue Code TAX
VICP Reform and Excise Tax Vaccine Injury Compensation Program
| Lobbyist | Covered position, as disclosed |
|---|---|
| MATTHEW STROIA | — |
| JENNIFER SWENSON WALTON | — |
| ANGELA BOOTHE WILES | — |
Trade (domestic/foreign) TRD
International Supply Chain Global Access Tariffs Non-Tariff Trade Barriers
| Lobbyist | Covered position, as disclosed |
|---|---|
| ELISSA ALBEN | — |
| PAULA BURG | — |
| FRANCISCO CARRILLO | — |
| STEPHEN CLAEYS | — |
| EMILY MUELLER | — |
| CATHERINE ROBINSON | — |
| MATTHEW STROIA | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.